Dyne to seek accelerated approval of DMD drug on Phase I/II data
Dyne Therapeutics intends to submit a biologics licence application to the FDA for accelerated approval in Q2 2026.
Structure Therapeutics announces positive results from aleniglipron trial
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM
Kallyope’s migraine drug advances to pivotal trial
ASH 2025: Cullinan’s T-cell engager boasts potential across p53 AML subset
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
Analysis
View More
Themes
View MorePatient-centric approaches thrive on wearables and remote access in trials
Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.
More themes
Data Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus Magazine
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
AI-automated IVF procedures represent a new era in fertility treatment
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal